Correction to Lancet Gastroenterol Hepatol 2018; 4: 435–44

Slides:

Advertisements

Similar presentations

Advances in shaking technologies Wolf Klöckner, Jochen Büchs Trends in Biotechnology Volume 30, Issue 6, Pages (June 2012) DOI: /j.tibtech

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Venezuela: violence, human rights, and health-care realities

Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention Sharon J. Hutchinson, Sheila M.

Pharmacogenetics and future drug development and delivery

Élise Roy, Jean-François Boudreau, Jean-François Boivin

Thank God for Richard Dawkins?

Volume 391, Issue 10123, Pages (March 2018)

Optimum timing of treatment for hepatitis C infection relative to liver transplantation Dr Audrey Coilly, MD, Bruno Roche, MD, Prof Jean-Charles Duclos-Vallée,

Author gender in The Lancet journals

Hepatitis B and C in Tonkolili Province, Sierra Leone

Infections related to totally implantable venous-access ports

Regulating illegal drug markets: what legal markets can teach us

Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis Christian Løvold Storhaug, MS, Svein.

John N Nkengasong, Philip Onyebujoh The Lancet

Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage.

Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study Matthew Waxman, MD,

No Impact of Hepatitis C Virus Infection on Mortality Among Drug Users During the First Decade After Seroconversion Bart Grady, Charlotte van den Berg,

Aspirin in the prevention of cancer – Author's reply

Volume 376, Issue 9743, (September 2010)

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Gender myths in global health

Gene therapy in haematology and oncology

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Volume 15, Issue 9, Pages (August 2016)

Brian J Coburn, Sally Blower The Lancet Infectious Diseases

Retracted: Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment Jonathan Pearson-Stuttard, BMBCh,

Can plagues be predicted, prevented?

Disease and stigma The Lancet Volume 354, (December 1999)

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,

Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H

Arnaud Chiolero The Lancet Public Health

An update on Zika virus infection

HIV myths should not be resuscitated

Challenges to eliminate rabies virus infection in China by 2020

Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis Ulla Beijer, PhD, Achim Wolf, MSc, Dr.

Pharmacogenetic testing in the UK clinical setting

Maternal pre-pregnancy infection with hepatitis B virus and the risk of preterm birth: a population-based cohort study Jue Liu, PhD, Shikun Zhang, MD,

Interpreting Hepatitis B Surface Antigen Levels: Useful Clinical Test or Just Another Confusing Assay? Brian J. McMahon, MD, Brenna C. Simons, PhD Clinical.

DEPARTMENT OF ERROR The Lancet Volume 362, Issue 9385, (August 2003)

Michael Charlton Clinical Gastroenterology and Hepatology

Effect of development assistance on domestic health expenditures

A voracious creature The Lancet Volume 358, (December 2001)

Traveling Internationally: Avoiding and Treating Travelers' Diarrhea

Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.

What would happen if we stopped vaccination?

Metabolic mediators of body-mass index and cardiovascular risk

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Drama therapy The Lancet Volume 383, Issue 9933, (June 2014)

Confessions of a journal junkie

Infant-feeding patterns and HIV-1 transmission

Telling it like it isn't: truth and lies in a post-9/11 world

Volume 15, Issue 9, Pages (August 2016)

Brendan Campbell, Benny Liu, Taft Bhuket, Robert J. Wong

Volume 393, Issue 10178, Pages (March 2019)

Thank God for Richard Dawkins?

Low-technology approaches

Sharon J. Hutchinson, Sheila M. Bird, David J. Goldberg

Thank you to our diverse (but not diverse enough) reviewers

Prescription for change

Steven A Narod The Lancet Volume 349, Issue 9068, (June 1997)

Infections related to totally implantable venous-access ports

Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment Jonathan Pearson-Stuttard, BMBCh, Bin Zhou,

A remarkable report card on progress in COPD

Difficulties of surgery in the developing world: a personal view

Clinical Gastroenterology and Hepatology

Improving management of neonatal infections

Tapestry of life The Lancet Volume 375, Issue 9723, (April 2010)

Autism, maths, and sex: the special triangle

A disease of the osteoblast

Presentation transcript:

Correction to Lancet Gastroenterol Hepatol 2018; 4: 435–44 The Lancet Gastroenterology & Hepatology Volume 4, Issue 6, (June 2019) DOI: 10.1016/S2468-1253(19)30126-8 Copyright © 2019 Elsevier Ltd Terms and Conditions

Figure 3 Map of PAF of HCV transmission associated with injection drug use, 2018–30 PAF is the percentage of all new HCV infections that would be prevented over the period 2018–30 if the additional HCV transmission risk attributable to IDU was removed. Countries in grey were not modelled because of a paucity of data. PAF=population attributable fraction. HCV=hepatitis C virus. IDU=injection drug use. The Lancet Gastroenterology & Hepatology 2019 4, DOI: (10.1016/S2468-1253(19)30126-8) Copyright © 2019 Elsevier Ltd Terms and Conditions